Cytokinetics, Incorporated, a late-stage biopharmaceutical company, focuses on discovering, developing, and commercializing muscle activators and inhibitors as potential treatments for debilitating diseases in the United States. The company develops small molecule drug candidates primarily engineered to impact muscle function and contractility. Its drug candidates include omecamtiv mecarbil, a novel cardiac myosin activator that is in Phase III clinical trial in patients with heart failure. It also develops CK- 089, a fast skeletal muscle troponin activator that is in Phase I clinical trial; CK-586, a small molecule cardiac myosin inhibitor, that is in Phase II clinical trial; and aficamten, a novel, oral, small molecule cardiac myosin inhibitor which is in Phase III clinical trial discovered for the treatment of hypertrophic cardiomyopathy. It has a strategic alliance with Ji Xing Pharmaceuticals Limited; and a collaboration and license agreement for the development and commercialization of aficamten in Japan for the treatment of patients with obstructive and non-obstructive hypertrophic cardiomyopathy. Cytokinetics, Incorporated was incorporated in 1997 and is headquartered in South San Francisco, California.
Market Challenges | Learn about Cytokinetics' strategies to navigate commercialization hurdles, including securing favorable reimbursement and differentiating aficamten in a competitive landscape |
Financial Outlook | Analysts project EPS of -$5.38 for FY1 and -$5.13 for FY2, reflecting ongoing R&D investments. Average price target ranges from $78 to $95, indicating growth potential |
Pipeline Expansion | Delve into Cytokinetics' robust pipeline, including CK-586 for heart failure and CK-089 for muscular dystrophy, showcasing the company's strategic growth beyond cardiovascula |
Aficamten's Promise | Explore Cytokinetics' lead drug candidate aficamten, poised to revolutionize hypertrophic cardiomyopathy treatment with its differentiated profile and market potential |
Metrics to compare | CYTK | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipCYTKPeersSector | |
---|---|---|---|---|
P/E Ratio | −7.6x | −0.1x | −0.5x | |
PEG Ratio | −2.23 | 0.02 | 0.00 | |
Price / Book | −33.2x | 2.4x | 2.6x | |
Price / LTM Sales | 243.6x | 12.1x | 2.9x | |
Upside (Analyst Target) | 96.4% | 319.6% | 57.2% | |
Fair Value Upside | Unlock | 3.8% | 8.9% | Unlock |